Demonstrating Biosimilarity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Demonstrating Biosimilarity
Extensive comparability testing is required to ensure that biosimilars have comparable profiles to their reference products.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 42-45

Conclusion
The EMA Committee for Medicinal Products for Human Use have issued a number of guidelines relevant to biosimilars that detail the requirements for market approval. The EMA guidelines cover a range of issues including manufacturing, measurement and comparability, chemical and biological analysis, and clinical trial requirements. In addition to the pharmaceutical, chemical, and biological data normally required for a generic-drug application, application for market approval of biosimilar products require additional toxicological and other nonclinical and clinical data.

The key is to demonstrate that the biosimilar product is similar to the reference product in terms of quality, safety, and efficacy. Products are dealt with on a case-by-case basis. The 2009 Biologics Price Competition and Innovation Act directed the US FDA to develop a regulatory framework in support of developing biosimilars and also defined the pathway to achieve drug approval. This pathway is based on a risk-based approach using what the agency has termed "totality of evidence." Working with a partner who has experience with the regulators for both innovator and biosimilar products will help to build this body of evidence.

Alison Armstrong is director of development services at BioReliance Ltd., Todd Campus, West of Scotland Science Park, Glasgow G20 0XA.

References
1. EMA, "Multidisciplinary: Biosimilar," http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp, accessed July 22, 2013.
2. ICH, Q2(R1) Validation of Analytical Procedures, Step 4 version (1994).
3. S. Deechongkit et al., J Pharm. Sci. 95 (9) 1931–1943 (2006).
4. FDA, Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Rockville, MD, Feb. 2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here